05th week of 2010 patent applcation highlights part 43 |
Patent application number | Title | Published |
20100028293 | Agents for control of codling moth in fruit orchards - The invention provides a method for identifying volatile insect repellents and/or attractants released from their non-volatile glycosides by the action of -glucosidase on plant tissue extracts. By this method, geraniol was identified as codling moth repellent and methyl salicylate, (2R,5R)-theaspirane, and (2S,5R)-theaspirane, and to a lesser extent linalool and benzyl alcohol as codling moth attractants. The invention provides compositions comprising said repellent and attractants and methods for control of codling moth in fruit, preferably apple, orchards. | 2010-02-04 |
20100028294 | Methods and compositions for attracting or repelling cockroaches - A method for attracting cockroaches to an object or area, involving treating said object or area with a cockroach attracting composition containing a cockroach attractant effective amount of at least one compound selected from the group consisting of methyl, ethyl, propyl, or butyl esters of C | 2010-02-04 |
20100028295 | Pesticide Composition - The present invention relates to novel pesticide compositions in the form of a gel material or a solid material which are suitable for combating arthropod pests, in particular insects. The pesticide composition in the form of a gel or solid contains
| 2010-02-04 |
20100028296 | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease - Peptides derived from anti-inflammatory cytokines, such as IL-10, are disclosed for use in treatment of neurodegenerative diseases and neuropathic pain indications, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease and trigeminal neuralgia. | 2010-02-04 |
20100028297 | COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS - The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents. | 2010-02-04 |
20100028298 | INTERFERON TYPE I SUPPORTING COMPOUNDS - The present invention relates to the use of cyclic peptides, in particular of vioprolides for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in enhancing and/or supporting interferon type I1 like interferon alpha or interferon beta, treatment or prevention of diseases, disorders or conditions. Further, the present invention relates to new pharmaceutical compositions comprising specific cyclic peptides, in particular, vioprolides, and type I interferon and its use in the treatment of various diseases, in particular, in the treatment or prevention of infectious diseases, cancers etc. Finally, the present invention provides methods for preventing or treating diseases, disorders or conditions susceptible to type I interferon treatment or prevention. | 2010-02-04 |
20100028299 | Methods and compositions of treating a flaviviridae family viral infection - Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. | 2010-02-04 |
20100028300 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS - Compounds of formula I: | 2010-02-04 |
20100028301 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT - The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections. | 2010-02-04 |
20100028302 | Use of IGFBP-2 in Senescence Diseases and for the Maintenance of Organ Functions - The present invention relates to the use of an IGFBP-2 (insulin-like growth factor binding protein-2) molecule for the production of a pharmaceutical composition for the regulation of senescence processes in cells, tissues and/or organs for the maintenance and control of tissue and/or organ functions and/or for the treatment or alleviation of senescence symptoms or early senescence, wherein the IGFBP-2 molecule is selected from the group of an IGFBP-2 polypeptide or of a functional fragment thereof and of a nucleic acid encoding an IGFBP-2 polypeptide or a functional fragment or derivative thereof. Moreover, corresponding methods of treatment are provided. The use of IGFBP-2 in the preparation of a pharmaceutical composition in the medical intervention of cachexia is described. | 2010-02-04 |
20100028303 | CONTROL OF PLANT DISEASES AND ENHANCING PLANT GROWTH USING A COMBINATION OF A TRICHODERMA VIRENS SPECIES AND A RHIZOSPHERE COMPETENT TRICHODERMA HARZIANUM SPECIES - The combination of a | 2010-02-04 |
20100028304 | PESTICIDAL COMPOSITIONS - A pesticidal composition comprising synergistically effective amounts of at least one anthranilamide compound represented by the formula (I) or its salt and other pesticide: wherein each of R | 2010-02-04 |
20100028305 | Methods for the treatment of lysosomal storage disorders - Provided herein are methods for the treatment of lysosomal storage disorders characterized by a missing or defective secreted lysosomal enzyme. Such lysosomal storage disorders include, but are not limited to neuronal ceroid lipofuscinoses. The disclosed methods involve the transplantation of human multipotent neural stem cells into the CNS of patients suffering from the lysosomal storage disorder. Also provided herein are methods of reversing or slowing the progression of neurodegeneration in patients suffering from or at risk of developing neuronal ceroid lipofuscinoses. | 2010-02-04 |
20100028306 | Amnion-Derived Cell Compositions, Methods of Making and Uses Thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 2010-02-04 |
20100028307 | PLURIPOTENT STEM CELL DIFFERENTIATION - The present invention relates to the field of pluripotent stem cell differentiation. The present invention provides methods for the differentiation of pluripotent stem cells on a human feeder cell layer. In particular, the present invention provides an improved method for the differentiation of pluripotent stem cells into pancreatic endocrine cells using a human feeder cell layer. | 2010-02-04 |
20100028308 | METHODS TO MAINTAIN, IMPROVE AND RESTORE THE CARTILAGE PHENOTYPE OF CHONDROCYTES - The present invention relates to regulatory cells, which are capable of restoring, maintaining or improving the stable cartilage phenotype of expanded and passaged chondrocytes. These regulatory cells are also capable of directing precursor and stem cells into the chondrogenic lineage. An enriched population of regulatory cells can be obtained by harvesting the non-adherent cells in the culture medium of a monolayer culture of PO chondrocytes. | 2010-02-04 |
20100028309 | METHOD FOR DIRECTED CELL IN-GROWTH AND CONTROLLED TISSUE REGENERATION IN SPINAL SURGERY - The present invention relates to a method for directed cell in-growth and controlled tissue regeneration to prevent post-surgical or post-traumatic adhesion and fibrosis formation on the injured surface of a tissue selected from the group consisting of spinal column tissue, dura mater, and spinal nerves in a mammal, comprising the step of providing, covering and separating the tissue with a bioactive biofunctional, non-porous, microscopically multilayered collagen foil biomatrix, and to a method for treating a defect in a mammal comprising the step of providing, covering and separating said tissue with a bioactive biofunctional, non-porous, microscopically multilayered collagen foil biomatrix. | 2010-02-04 |
20100028310 | Composition for Transplantation Comprising Adipose Stem Cells or Adipocytes - The present invention relates to a composition for transplantation in a physiologically compatible buffer solution comprising, (a) a transplant-cell selected among an adipose stem cell, an adipocyte, adipose tissues (fat tissue) and a mixture thereof; and (b) a semi-solid substance derived from a living body or a biodegradable substance selected among a hyaluronic acid, collagen, elastin, thrombin, chondroitin sulfate, albumin and a mixture thereof. | 2010-02-04 |
20100028311 | USING OF SCAFFOLD COMPRISING FIBRIN FOR DELIVERY OF STEM CELLS - The invention generally relates to the field of delivery of cells to desired tissue sites, prolonged retention of the cells at the sites, and integration of cells into an area of interest for increased therapeutic effect. The invention provides, in part, compositions and methods for treating ischemia in a subject in need thereof. In some aspects, the methods of treatment comprise the administration of a fibrin scaffold or fibrin clot comprising stem cells. | 2010-02-04 |
20100028312 | Stably transformed bone marrow-derived cells and uses thereof - The invention provides compositions comprising genetically modified bone marrow cells and related therapeutic and diagnostic methods. Transduced bone marrow cells can be therapeutically administered to a subject, such as a human patient to provide for the expression of an encoded protein in the subject in need thereof. | 2010-02-04 |
20100028313 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS - The present invention concerns methods and compositions for prophylactic or therapeutic treatment of skin disorders by administering therapeutically or prophylactically effective amounts of a probiotic. The present invention is also concerned with the treatment of symptoms of skin disorders. | 2010-02-04 |
20100028314 | Bacillus Amyloliquefaciens Strain - The present invention relates to | 2010-02-04 |
20100028315 | Dried and/or microencapsulated saccharomyces cerevisiae cells with a high content of (s)-(+)-s-adenosyl-l-methionine, process for their preparation, and compositons containing said cells - Disclosed are dried and/or microencapsulated | 2010-02-04 |
20100028316 | MODERATING THE EFFECT OF ENDOTOXINS - The present invention relates to the use of an oral composition comprising yeast extract, in the manufacture of an oral composition to treat the effects of infection by pathogenic bacteria such as | 2010-02-04 |
20100028317 | Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators - Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace. | 2010-02-04 |
20100028318 | AGENT FOR RELIEF OR PREVENTION OF XEROSTOMIA - The present invention has its object to provide a safer and highly effective composition capable of relieving or preventing xerostomia. The present invention relates to an agent for relieving or preventing xerostomia comprising an oxidized coenzyme Q and/or a reduced coenzyme Q as active ingredients, a composition containing the agent for relieving or preventing xerostomia in a form of a food product, a health food, a dietary supplement, a supplement, an oral health care product, a medicament, a quasi drug, a pet food, a feed or the like, and a method for treating xerostomia and a method for reducing risks of xerostomia comprising administering the composition. | 2010-02-04 |
20100028319 | COMPOSITION FOR PREVENTION OR TREATMENT OF DIABETES - The present invention aims to provide a composition which has an extremely broad range of applications, has an excellent safety, and can be used for preventing, ameliorating, or therapeutically-treating diabetes. | 2010-02-04 |
20100028320 | Methods and Compositions for Inhibiting Diseases of the Central Nervous System - Methods and compositions for treating central nervous system diseases and disorders are disclosed. | 2010-02-04 |
20100028321 | DRUG TARGET FOR PREVENTING AND TREATING PERIODONTAL DISEASE, IMPROVING HEALING OF PERIODONTAL WOUNDS AND PROMOTING ORAL HEALTH - The present invention relates to the use of a component of the plasminogen-activating pathway and use of compounds which have the capacity to activate plasminogen directly or via the plasminogen-activating pathway, for prophylaxis, prevention and treatment of periodontal disease including peri-implantitis, healing of periodontal wounds and prompting oral health in human and non-human subjects. | 2010-02-04 |
20100028322 | ANTIMETASTATIC EFFECT ON HUMAN CELL DISORDERS - Use of recombinant human lysozyme in the preparation of a medicament for controlling life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering to a subject in need thereof therapeutically effective doses of recombinant human lysozyme to elicit said antiproliferative and antimetastatic effects. | 2010-02-04 |
20100028323 | VERMIN EXTERMINATION USING LYSOZYME, SALT OR BIOLOGICAL FRAGMENT THEREOF, OR LYSOZYME-RELATED PEPTIDE AS AN EGG RECOGNITION PHEROMONE - The present invention provides a mimetic egg comprising lysozyme, a salt or biological fragment thereof or a lysozyme-related peptide and an active ingredient in its base material mimicking an egg of a vermin; and a vermin exterminating method using the mimetic egg. | 2010-02-04 |
20100028324 | Creating Designer Antimicrobials; Peptidoglycan Hydrolase Module Shuffling - The invention concerns a nucleic acid encoding a recombinant bifunctional fusion peptidoglycan hydrolase protein formed from a nucleic acid encoding a peptidoglycan hydrolase module and a nucleic acid encoding a second peptidoglycan hydrolase module. The fusion, dual (or multiples thereof) peptidoglycan hydrolase modules can be used to treat disease caused by the bacteria for which the individual modules of the fusion protein are specific. | 2010-02-04 |
20100028325 | New Combination Of Cationic Preservatives With Taste-Masking Components - Use of cationic surfactants, derived from the condensation of fatty acids and esterified dibasic amino acids, of the formula (1): | 2010-02-04 |
20100028326 | DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON PROTEINS DIFFERENTIALLY EXPRESSED IN SERUM - Mouse proteins differentially expressed in serum, in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic white adipose tissue have been identified, as have corresponding human proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequalae. | 2010-02-04 |
20100028327 | NOVEL LOW DENSITY LIPOPROTEIN BINDING PROTEINS AND THEIR USE IN DIAGNOSING AND TREATING ATHEROSCLEROSIS - Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided. | 2010-02-04 |
20100028328 | TOPICAL TREATMENT FOR DISEASES OF EYE SURFACE - A topical eye solution for the treatment of corneal, scleral, or conjunctival diseases. In one embodiment of the present invention, the eye solution comprises a saline-based fluid, and an effective amount of at least one therapeutic compound or agent, wherein when at least one drop of the eye solution is applied to the surface of an eye, the therapeutic compound or agent is released to the cornea and conjunctiva of the eye. | 2010-02-04 |
20100028329 | METHOD FOR PRODUCING GLYCOSYLATED INDOLE COMPOUND AND ANTIBODY AGAINST THE COMPOUND - This invention provides a method of producing a large amount of an α-form or β-form of N-pyranosyl-tryptophan having a specified structure and preparing an antibody therefrom. The method comprises a step of allowing a pyranose compound to react with a 3-pyrazyl-indole compound in the presence of a first base to obtain a 1-pyranosyl-3-pyrazyl-indole compound, and a step of treating the 1-pyranosyl-3-pyrazyl-indole compound with an acid, treating the resultant with a hydrogenation catalyst, and further treating the resultant with a second base to synthesize N-pyranosyl-tryptophan, thereby producing an antibody therefrom. | 2010-02-04 |
20100028330 | METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES - This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders. | 2010-02-04 |
20100028331 | Antagonists of activin-actriia and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2010-02-04 |
20100028332 | Antagonists of actriib and uses for increasing red blood cell levels - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2010-02-04 |
20100028333 | RECEPTOR FOR AMYLOID BETA AND USES THEREOF - Compositions and methods for identifying modulators of sortilin are described. The methods are particularly useful for identifying analytes that antagonize sortilin s effect on processing of amyloid precursor protein to Aβ peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease. | 2010-02-04 |
20100028334 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY - A pharmaceutical composition comprising an antimicrobial agent and an enhancer of an antimicrobial agent, wherein the enhancer of an antimicrobial agent is an inhibitor of gene, that by inactivating the gene product potentiates the effectiveness of the antimicrobial agent. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the antimicrobial agent is an antimicrobial peptide such as a polymyxin, for example but not limited to colistin. In some embodiments of the present invention provides methods to treat and/or prevent infection of a subject with a microorganism by administering a pharmaceutical composition comprising an antimicrobial agent and an enhancer of an antimicrobial agent. In some embodiments, the present invention provides methods to inhibit growth of a microorganism by administering a pharmaceutical composition comprising an antimicrobial agent and an enhancer of an antimicrobial agent. | 2010-02-04 |
20100028335 | Compositions and Methods to Treat Bone Related Disorders - The present invention relates to the use of modulators of the sclerostin: sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin: sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided. | 2010-02-04 |
20100028336 | Anti-Mesothelin Antibodies - This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments. | 2010-02-04 |
20100028337 | METHODS AND COMPOSITIONS FOR MODULATING HYPERSTABILIZED C-MET - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein. | 2010-02-04 |
20100028338 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER - A combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis is disclosed. The patient is treated with a camptothecin derivative and one or more chemotherapeutic agents selected from a microtubule active agent; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase II inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; and ionizing radiation. | 2010-02-04 |
20100028339 | COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2010-02-04 |
20100028340 | ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF - The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia. | 2010-02-04 |
20100028341 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM - The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences | 2010-02-04 |
20100028342 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR ANTAGONISTS FOR MODULATION OF WEIGHT AND LIPOSITY - The invention is directed to the use of insulin-like growth factor receptor antagonists for treatment of obesity. The IGF-IR antagonists are administered alone or in combination with other anti-obesity drugs. | 2010-02-04 |
20100028343 | Il-17 homologous polypeptides and therapeutic uses thereof - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2010-02-04 |
20100028344 | CONDITIONED CELL IMMUNIZATION - The present invention provides methods and compositions for generating modulators capable of binding to antigens presented by a cell that has been exposed to cellular conditioning. The present invention also includes methods and compositions for the prevention, treatment and diagnosis of disorders using the antigen modulators. The present invention further provides methods for identifying novel molecular targets for the treatment of different disorders. | 2010-02-04 |
20100028345 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS - The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein. | 2010-02-04 |
20100028346 | NOVEL SYNERGISTIC EFFECTS - The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone or the administration of one or more of the drug(s) without the conjugate. The present invention is also directed to compositions comprising at least one conjugate and at one or more of chemotherapeutic agent and to methods of treating cancer using at least one conjugate and at least one or more of chemotherapeutic agent (s). The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of one or more chemotherapeutic agent(s) and at least one conjugate. In each case, such combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the anticancer agent(s) alone. | 2010-02-04 |
20100028347 | ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 - Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti -VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies. | 2010-02-04 |
20100028348 | Compositions and Methods for Inhibiting an Isoform of Human Manganese Superoxide Dismutase - The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as heart failure. | 2010-02-04 |
20100028349 | Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 2010-02-04 |
20100028350 | PREVENTING IL-2 MEDIATED INFLAMMATION IN EPITHELIAL CELLS - The present invention provides new methods for treating, minimizing and/or preventing inflammatory injury involving IL-2 activity on epithelial cells expressing IL-2 receptors. Methods for reducing or preventing inflammatory injury in a tissue/organ comprise inhibiting IL-2 receptor activity in cells of the tissue/organ. | 2010-02-04 |
20100028351 | ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-amyloid antibody, including isolated nucleic acids that encode at least one anti-amyloid antibody, amyloid, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2010-02-04 |
20100028352 | COMPOSITIONS AND METHODS COMPRISING GLYCYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2010-02-04 |
20100028353 | ANTI-AMYLOID IMMUNOGENIC COMPOSITIONS, METHODS AND USES - Polypeptide based on a tandem array of repeats of the N-terminal 7 amino acids of Aβ42, preferably positioned within the active loop site of a carrier such as bacterial thioredoxin (Trx) are useful for treating and/or preventing Alzheimer's disease. Antibodies raised against these recombinant constructs were found to have a very strong affinity for Aβ42. | 2010-02-04 |
20100028354 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE - Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual. | 2010-02-04 |
20100028355 | HIMF AND BTK IN PULMONARY, CARDIAC AND INFLAMMATION DISORDERS - Hypoxia induced mitogenic factor (HIMF) is a member of the “found in inflammatory zone” (FIZZ)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown. We identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through GST-HIMF pull-downs and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that BTK was recruited to the leading edge of the cells. We also demonstrated that BTK and the closely related tyrosine kinase Fyn, colocalized at the growth cone process in these cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 minutes. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells, which was completely blocked by the BTK inhibitor, LFM-A13. In vivo studies, using the rat hindlimb ischemia model, revealed that HIMF can stimulate angiogenesis in the hypoxic tissue probably through inducing the migration of endothelial progenitor cells (EPCs) to areas of active angiogenesis. Our results indicate that HIMF may acts as a chemotactic molecule in stimulating the migration of leukocytes/EPCs from bone marrow to targeted tissues through activation of the BTK pathway. | 2010-02-04 |
20100028356 | METHOD OF DIAGNOSING A NEURODEGENERATIVE DISEASE - The present invention provides a method for diagnosing a neurodegenerative disease or for determining the predisposition of a subject to a neurodegenerative disease. In particular, the methods of the present invention comprise detecting a marker linked to map position 9p21, e.g., a marker within an opioid receptor sigma 1 (OPRS1) gene or an expression produce thereof. The present invention also provides a method for identifying new markers that are associated with a neurodegenerative disease. The present invention also provides mutant forms of an OPRS1 gene or an expression product thereof and reagents for detecting those mutations. | 2010-02-04 |
20100028357 | Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2010-02-04 |
20100028358 | Compositions and Methods for Controlling Tissue Factor Signaling Specificity - Compositions and methods for treating a disease dependent upon tissue factor/factor VIIa signaling in a mammalian subject is provided. The methods comprise administering an inhibitor of tissue factor signaling to the mammalian subject. The inhibitor is effective in reducing the incidence of disease in the mammalian subject. Also provided are methods of screening for modulators of tissue factor/factor VIIa signaling. | 2010-02-04 |
20100028359 | ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products. | 2010-02-04 |
20100028360 | METHODS FOR THE MODULATION OF BRAIN PROGESTAGEN SIGNALING IN THE PREVENTION AND TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES - The present invention relates to methods for modulating progestagen signaling for treating neurological disorders or neurodegenerative disease, or preventing or delaying its onset in individuals deemed by competent observation and testing to be susceptible thereto. Progestagens can be administered to elevate serum and brain levels of progestagens and induce neurogenesis. Progestagen therapy may prevent some of the neurodegenerative and cognitive changes associated with developmental and aging associated neurological disorders and neurodegenerative diseases. Progestagen therapy together with suppression of GnRH, kisspeptin, LH and/or FSH signaling also may be used for treating neurological disorders or neurodegenerative diseases. The invention also relates to methods for inhibiting or delaying blastulation during embryogenesis, and neurogenesis during embryogenesis, fetal, neonatal, childhood, puberty or adult life. Blocking progestagen, estrogen and/or opioid signaling with receptor antagonists will inhibit neurogenesis. The invention also relates to using progestagens in vitro to induce neurogenesis in embryonic or adult stem cells. | 2010-02-04 |
20100028361 | BRAIN-DERIVED GONADOTROPINS AND COGNITION - A method of treating or preventing neurodegenerative disease in a subject, the method includes administering to the subject a therapeutically effective amount of at least one physiologically acceptable agent that modulates levels, production, and/or function of brain-derived hormones of the hypothalamic-pituitary-gonadal (HPG) axis or their receptors. | 2010-02-04 |
20100028362 | MODULATION OF T HELPER CELL-MEDIATED IMMUNE RESPONSES - Provided herein are methods for modulating one or more of a T-helper cell or monocyte lineage cell-mediated immune response in a subject, the method comprises administering to the subject an effective amount of a compound which binds to surface membrane immunoglobulin D (smIgD). Also provided are methods of diagnosis of one or more of a T-helper cell or monocyte lineage cell-mediated immune disease, and compositions and kits for use in such methods. | 2010-02-04 |
20100028363 | METHODS FOR TREATING PSORIASIS - The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 2010-02-04 |
20100028364 | INHIBITION OF SOX9 FUNCTION IN THE TREATMENT OF PROTEOGLYCAN-ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS - A method of treating a pathophysiological condition caused by the production of growth-inhibiting proteoglycans is provided. It is based on the finding that down-regulation of SOX9 results in decreased production of growth-inhibiting factors such as proteoglycans, and increased production of growth-promoting factors such as a laminin and fibronectin. The method of the present invention comprises the inhibition of SOX9 expression and function with an inhibitor such as an antisense oligonucleotide or a siRNA. | 2010-02-04 |
20100028365 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Methods and compositions are provided for the diagnosis and treatment of gastric cancers associated with amplification or overexpression of the c-Myb gene. | 2010-02-04 |
20100028366 | SYNERGISTIC EFFECT BETWEEN A CYANOGENIC SYSTEM AND ANOTHER OXIDATIVE INDUCING SYSTEM FOR TREATING TUMORS - The invention relates to a system capable of causing the death of tumor cells by activating caspase-independent apoptosis, comprising:
| 2010-02-04 |
20100028367 | SGP130/FC DIMERS - Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala | 2010-02-04 |
20100028368 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF - Compounds useful as antiproliferative agents according to formula (I): wherein Ar | 2010-02-04 |
20100028369 | Hazardous substance removing material and method for removing hazardous substance - It is an object of the present invention to provide a hazardous substance removing material, which efficiently captures hazardous substances derived from microorganisms such as bacteria or viruses and rapidly inactivates them, so as to minimize the their influences on human bodies, and which is able to allow an antibody to be supported on a carrier by a simple method, and which has an improved antibody use efficiency. The present invention provides a hazardous substance removing material consisting of a carrier on which an antibody and a polymer material having an affinity for Fc region of the antibody are supported. | 2010-02-04 |
20100028370 | MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUES - The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier. | 2010-02-04 |
20100028371 | Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals - The present invention relates to a non-human transgenic mammal whose genome comprises: i) a first transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding a rotavirus protein selected from VP2, VP4, VP6 and VP7 and wherein said cDNA comprises a secretion signal sequence; ii) at least a second transgene comprising a mammary gland specific transcriptional control region operably linked to cDNA encoding another said rotavirus protein and wherein said cDNA comprises a secretion signal sequence; and wherein said rotavirus proteins are secreted separately and auto-assembled in milk in rotavirus like particles (VLP) or aggregates of said rotavirus proteins. | 2010-02-04 |
20100028372 | STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS - An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a). | 2010-02-04 |
20100028373 | PEPTIDE VACCINES FOR CANCERS EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES - The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines. | 2010-02-04 |
20100028374 | C-TYPE LECTIN TRANSMEMBRANE ANTIGEN EXPRESSED IN HUMAN PROSTATE CANCER AND USES THEROF - A novel gene (designated PC-LECTIN) that is highly overexpressed in prostate cancer and its encoded protein is described. PC-LECTIN in normal human tissues is restricted to testis, but is highly expressed in prostate cancer. Consequently, PC-LECTIN provides a diagnostic and/or therapeutic target for prostate cancer. | 2010-02-04 |
20100028375 | VLP BASED VACCINE DELIVERY SYSTEM - An isolated protein comprising a VP1 amino acid sequence wherein one or more exposed loops within said VP1 has an insertion of an amino acid sequence from a virus protein other than VP1, and encoding nucleic acid, are provided. Typically, the virus protein other than VP1 is derived from an influenza virus and in particular, avian influenza virus. The isolated protein may have an insertion of amino acid sequence from a single protein or a plurality of proteins. Also provided are expression constructs, VLPs, pharmaceutical compositions, vaccines and methods of treatment that may be useful in the prophylactic and/or therapeutic treatment of any disease of viral origin, and in particular, influenza virus. | 2010-02-04 |
20100028376 | PHARMACEUTICAL AND COSMETIC USE OF EXTRACTS FROM ALGAE OBTAINABLE FROM SALINE HOT WATER SOURCES - The invention provides the use of extracts from algae for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that extracts from algae obtainable from saline hot water sources exhibit a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that such algae extracts induce markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induce collagen expression in dermal fibroblasts and inhibit UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6). | 2010-02-04 |
20100028377 | Recombinant RSV Virus Expression Systems And Vaccines - The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene. | 2010-02-04 |
20100028378 | TOXIN-ANTITOXIN SYSTEM AND APPLICATIONS THEREOF - The present invention relates to the discovery of a toxin-antitoxin system in opportunistic human pathogen | 2010-02-04 |
20100028379 | METHODS OF VACCINE ADMINISTRATION - This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein. | 2010-02-04 |
20100028380 | B CELL-BASED VACCINE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN - The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor. | 2010-02-04 |
20100028381 | FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS - The present invention provides pharmaceutical compositions that include an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel. In another aspect, the present invention also provides a method of eliciting an antigen-specific immune response in a subject. Generally, the method includes administering to the subject a pharmaceutical composition comprising an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel, in an amount effective to generate an immune response in the subject against the antigen. In yet another aspect, the present invention also provides a method of treating a condition in a subject. Generally, the method includes administering to the subject a pharmaceutical composition comprising an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel, in an amount effective to ameliorate at least one symptom or clinical sign of the condition. | 2010-02-04 |
20100028382 | Lentival Vector-Based Vaccine - Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed. | 2010-02-04 |
20100028383 | Chemically defined stabiliser - The present invention relates to a stabiliser composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabiliser composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabiliser composition with a biological molecule and/or a micro-organism; to the use of such a stabiliser composition, and of vaccines prepared therewith. | 2010-02-04 |
20100028384 | YEAST EXPRESSED CLASSICAL SWINE FEVER VIRUS GLYCOPROTEIN E2 AND USE THEREOF - A glycoprotein E2 of classical swine fever virus (CSFV) expressed in a recombinant yeast system. The recombinant E2 protein (yE2) is able to form a homodimer, exhibits glycosylation conformation and possesses correct immunogenicity. An anti-CSFV vaccine can be provided with yE2 as a major active ingredient to induce high titers of neutralizing antibody in vaccinated pigs, and to induce a protection against CSFV infection. | 2010-02-04 |
20100028385 | TREATMENT OF EXCESS CERUMEN SECRETION - Presently descibed are methods useful in treating outer ear conditions generally associated with the secretion of cerumen. The methods comprise the step of locally administering a therapeutically effective amount of neurotoxin such as a botulinum toxin to the ear canal of a patient. The conditions to be treated are generally associated with excess secretion of cerumen or the build-up of cerumen in the ear canal of a patient. Such conditions can include, but are not limited to, conductive hearing loss, pain and cough, for example. | 2010-02-04 |
20100028386 | RECOMBINANT P. FALCIPARUM MEROZOITE PROTEIN-142 VACCINE - In this application is described the expression and purification of a recombinant | 2010-02-04 |
20100028387 | Biocompatible Coated Nanostructured Titanium Surfaces - Bioactive molecules have been coated on nanotubular structured titanium substrates by molecular plasma deposition. The coatings promote cell adhesion and are particularly suited for orthopedic implants that provide improved bone cell adhesion and new tissue growth. Nanodimensional features on titanium substrates are engineered using electrochemical anodization techniques. The nanostructured surfaces provide superior support for a wide selection of polypeptide coatings. | 2010-02-04 |
20100028388 | SYSTEM AND METHOD FOR TRANSDERMAL DRUG DELIVERY - In the preferred embodiment, the invention is a system for creating micropores in the skin for transdermal drug delivery through the micropores and includes: a chemical that dissolves or breaks down superficial layers of skin; a chemical delivery element that holds and delivers controlled volumes of the chemical to skin, creating micropores; and a base that is able to temporarily couple to skin, contains the chemical delivery elements, and may activate the chemical delivery elements to administer the chemical to skin. In the preferred embodiment, the invention is a method for delivering drugs transdermally that includes providing a carrier containing a chemical delivery element with a chemical to break down superficial layers of skin; placing the carrier into contact with skin; activating the chemical delivery element; allowing the chemical to break down superficial layers of skin and creating micropores; and providing a drug to be delivered transdermally through the micropores. | 2010-02-04 |
20100028389 | HYDROMORPHONE THERAPY - A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain. | 2010-02-04 |
20100028390 | Transdermal Delivery Device - A dermal, transdermal, mucosal or transmucosal delivery device includes a backing layer overlying an ingredient containing reservoir, and having a microprotrusion array attached thereto, a cover for the reservoir having at least one opening therethrough, an adhesive layer and a liner layer. Upon removal of the liner layer, the device may be placed over the desired area of the skin or mucosa and adhesively applied thereto allowing the ingredients to flow from the reservoir through the at least one opening to the skin or mucosa. | 2010-02-04 |
20100028391 | Cosmetics Comprising A Modified Organopolysiloxane - This invention relates to a cosmetics characterized in that it contains a gelling agent comprising an organopolysiloxane having a silicon-bonded organic group represented by general formula:R | 2010-02-04 |
20100028392 | Personal Care Article - A personal care article including a substrate having impregnated therein, applied thereon or arranged to substantially encase, a cosmetic composition which includes a hair modification active, wherein the pH of the composition is substantially less than 9.0, and at least a portion of the article has exfoliating properties. | 2010-02-04 |